Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITZ: Rituximab Plus Zanubrutinib vs Rituximab in Splenic Marginal Zone Lymphoma
NCT05735834Phase 3Active, not recruiting
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- May 2024
- Primary completion
- May 2029
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 8
01
Overview
A Phase 3 trial of zanubrutinib in splenic marginal zone lymphoma (SMZL), sponsored by International Extranodal Lymphoma Study Group. Started May 2024; status: active, not recruiting.
02
Drugs
zanubrutinib
03
Conditions
splenic marginal zone lymphoma (SMZL)
Beyond the preview
Go deeper on NCT05735834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05735834.